Tackling Symptoms of Vertigo

Tackling Symptoms of Vertigo

A common complaint, vertigo has a number of mostly benign causes, often treated with betahistine, which is thought to reduce endolymphatic pressure, allowing vestibular hair cells to function better. A Cochrane review of betahistine found that it may reduce symptoms of vertigo, and two more recent studies found positive benefits in patients with vertigo.

Modern Medicine – Issue 3 2021

Meeting the Challenges of Onychomycosis

Meeting the Challenges of Onychomycosis

Onychomycosis is an increasingly common fungal nail infection, chiefly caused by dermatophyte fungi. The disease is notoriously difficult to treat due to the deep-seated nature of fungi within the nail plate, prolonged treatment requirements due to poor nail plate absorption, poor patient adherence and frequent recurrences. Given the poor efficacy of currently available topical and systemic therapies, there is a renewed interest in exploring alternative treatment modalities for onychomycosis.

Modern Medicine – Issue 3 2021

Causes of Death in Heart Failure are Diverse

Causes of Death in Heart Failure are Diverse

Heart failure is a disease with a poor prognosis and its appearance frequently signals the final phase of many processes, one of the most prominent of which is ischaemic heart disease. Mortality is comparable to that of the most common cancers, with <50% four-year survival.1 Deaths due to non-cardiovascular causes, particularly cancer, may be increasing.

Modern Medicine – Issue 3 2021

Fenofibrate Targets Atherosclerosis Progression

Fenofibrate Targets Atherosclerosis Progression

Cardiovascular disease is the major cause of mortality worldwide and accounts for approximately 40% of all deaths. Dyslipidaemia is one of the primary causes of atherosclerosis and effective interventions to correct dyslipidaemia should form an integral component of any strategy aimed at preventing cardiovascular disease. Fibrates have played a major role in the treatment of hyperlipidaemia for more than two decades. Fenofibrate is one of the most commonly used fibrates worldwide

Modern Medicine – Issue 3 2021

Diagnosing and Treating Conjunctivitis

Diagnosing and Treating Conjunctivitis

Conjunctivitis is an inflammatory eye condition that involves the conjunctiva, a highly vascularised, thin and translucent membrane that covers the anterior portion of the sclera and the inside of the eyelids. It presents as a red or pink eye due to the dilation of the blood vessels that leads to hyperaemia and oedema of the conjunctiva. This process typically is associated with some form of discharge. The most common causes of conjunctivitis are viruses, bacteria, allergens and irritants.

Modern Medicine – Issue 3 2021

Immunomodulatory Effects of Azithromycin

Immunomodulatory Effects of Azithromycin

Macrolides (for example, azithromycin, erythromycin, fidaxomicin and clarithromycin) are a class of bacteriostatic antibiotics commonly employed in medical practice against various gram-positive and atypical bacterial species. Besides their antibacterial properties, macrolides are reported to also have anti-inflammatory and immunomodulatory effects.

Modern Medicine – Issue 3 2021

Diabetic Cardiomyopathy Mechanisms, screening and treatment imperatives

Diabetic Cardiomyopathy Mechanisms, screening and treatment imperatives

Diabetic cardiomyopathy (DCM) refers to structural and functional changes in the heart as a consequence of diabetes that may be independent of, or in combination with, coronary disease (microvascular, macrovascular or both). As DCM tends to be asymptomatic, it is important that GPs are vigilant in screening patients early for DCM and preventing progression.

Modern Medicine – Issue 3 2021

Moxonidine for Hypertension in Metabolic Syndrome

Moxonidine for Hypertension in Metabolic Syndrome

The centrally acting antihypertensive, moxonidine, reduces blood pressure (BP) in mild-to-moderate hypertensive patients as effectively as most first-line antihypertensives when used as monotherapy, and also in combination with other antihypertensive agents. It improves the metabolic profile in patients with hypertension and diabetes mellitus or impaired glucose tolerance, is well tolerated, has a low potential for drug interactions and may be administered once daily in most patients.
 

Modern Medicine – Issue 3 2021

Glycosaminoglycan Replacement Targets Painful Bladder

Glycosaminoglycan Replacement Targets Painful Bladder

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating chronic disease characterised by discomfort or recurrent abdominal and pelvic pains in the absence of urinary tract infections. Although the aetiology is unknown, there is increasing evidence that increased bladder layer permeability is linked to the symptoms of interstitial cystitis or painful bladder.

Modern Medicine – Issue 3 2021